Cargando…
Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
Long-acting injectable antipsychotics (LAIs) offer many benefits to patients with schizophrenia spectrum disorder (SSD). They are used with very different frequencies due to questions of eligibility or patients and prescribers’ attitudes towards LAI use. We assessed the prescribing rates of LAIs in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955244/ https://www.ncbi.nlm.nih.gov/pubmed/35330441 http://dx.doi.org/10.3390/jpm12030441 |
_version_ | 1784676289673691136 |
---|---|
author | Reymann, Stephan Schoretsanitis, Georgios Egger, Stephan T. Mohonko, Alexey Kirschner, Matthias Vetter, Stefan Homan, Philipp Seifritz, Erich Burrer, Achim |
author_facet | Reymann, Stephan Schoretsanitis, Georgios Egger, Stephan T. Mohonko, Alexey Kirschner, Matthias Vetter, Stefan Homan, Philipp Seifritz, Erich Burrer, Achim |
author_sort | Reymann, Stephan |
collection | PubMed |
description | Long-acting injectable antipsychotics (LAIs) offer many benefits to patients with schizophrenia spectrum disorder (SSD). They are used with very different frequencies due to questions of eligibility or patients and prescribers’ attitudes towards LAI use. We assessed the prescribing rates of LAIs in a large academic psychiatric hospital with a public service mandate in Switzerland and compared them with other countries and health care systems. To our knowledge, this study is the first to investigate inpatient LAI use in Europe. Medical records of all patients diagnosed with SSD discharged from the Clinic of Adult Psychiatry of the University Hospital of Psychiatry Zurich over a 12 month period from January to December 2019 were evaluated regarding the prescribed antipsychotics at the time of discharge. The rates of use of LAIs among all patients and among patients receiving LAI-eligible antipsychotic substances were assessed retrospectively. We assessed records of 885 patients with SSD. Among all cases, 13.9% received an LAI. Among patients who received antipsychotic medication that was eligible for LAI use (n = 434), 28.1% received an agent as an LAI. LAI use included paliperidone palmitate (69.9%), aripiprazole monohydrate (14.6%), risperidone (4.9%) and first-generation LAIs (9.8%). Compared to international frequencies of LAI administration, the prescription rate of LAIs in SSD patients was low. Further studies will evaluate patient- and prescriber-related reasons for this low rate. |
format | Online Article Text |
id | pubmed-8955244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89552442022-03-26 Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland Reymann, Stephan Schoretsanitis, Georgios Egger, Stephan T. Mohonko, Alexey Kirschner, Matthias Vetter, Stefan Homan, Philipp Seifritz, Erich Burrer, Achim J Pers Med Article Long-acting injectable antipsychotics (LAIs) offer many benefits to patients with schizophrenia spectrum disorder (SSD). They are used with very different frequencies due to questions of eligibility or patients and prescribers’ attitudes towards LAI use. We assessed the prescribing rates of LAIs in a large academic psychiatric hospital with a public service mandate in Switzerland and compared them with other countries and health care systems. To our knowledge, this study is the first to investigate inpatient LAI use in Europe. Medical records of all patients diagnosed with SSD discharged from the Clinic of Adult Psychiatry of the University Hospital of Psychiatry Zurich over a 12 month period from January to December 2019 were evaluated regarding the prescribed antipsychotics at the time of discharge. The rates of use of LAIs among all patients and among patients receiving LAI-eligible antipsychotic substances were assessed retrospectively. We assessed records of 885 patients with SSD. Among all cases, 13.9% received an LAI. Among patients who received antipsychotic medication that was eligible for LAI use (n = 434), 28.1% received an agent as an LAI. LAI use included paliperidone palmitate (69.9%), aripiprazole monohydrate (14.6%), risperidone (4.9%) and first-generation LAIs (9.8%). Compared to international frequencies of LAI administration, the prescription rate of LAIs in SSD patients was low. Further studies will evaluate patient- and prescriber-related reasons for this low rate. MDPI 2022-03-11 /pmc/articles/PMC8955244/ /pubmed/35330441 http://dx.doi.org/10.3390/jpm12030441 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Reymann, Stephan Schoretsanitis, Georgios Egger, Stephan T. Mohonko, Alexey Kirschner, Matthias Vetter, Stefan Homan, Philipp Seifritz, Erich Burrer, Achim Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland |
title | Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland |
title_full | Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland |
title_fullStr | Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland |
title_full_unstemmed | Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland |
title_short | Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland |
title_sort | use of long-acting injectable antipsychotics in inpatients with schizophrenia spectrum disorder in an academic psychiatric hospital in switzerland |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955244/ https://www.ncbi.nlm.nih.gov/pubmed/35330441 http://dx.doi.org/10.3390/jpm12030441 |
work_keys_str_mv | AT reymannstephan useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland AT schoretsanitisgeorgios useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland AT eggerstephant useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland AT mohonkoalexey useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland AT kirschnermatthias useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland AT vetterstefan useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland AT homanphilipp useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland AT seifritzerich useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland AT burrerachim useoflongactinginjectableantipsychoticsininpatientswithschizophreniaspectrumdisorderinanacademicpsychiatrichospitalinswitzerland |